Ki67 labeling confirmed that the combination treatment had a greater effect on S phase labeling of the tumor cells (reduced to a mean of 9.8 cells/field) compared to a mean of 58.3 cells/field with placebo, 49.1 cells per field with fulvestrant, and 28.7 cells per field with AZD4547 (Figure 7B-7C). Here, MKI67 is linked to neoplasm.